Document text
Principal Investigator: Deborah H. Fuller
Organization: NORTHERN ARIZONA UNIVERSITY
Fiscal Year: 2023
Award: $384,249
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY
Coccidioidomycosis, also known as Valley Fever (VF) impacts residents in arid regions of the world including
southwestern US, areas in South and Central America and in Mexico. Annual incidences are rising overall with
estimated increases in recent years of more than 200% in some areas. In addition, epidemiological studies
indicate that the geographical range of VF is expanding and up to 17-29% of community-acquired pneumonia in
these areas can be attributed to Coccidiodes infections. VF poses a significant and ongoing threat to human
health, but to date, there is no safe and effective vaccine licensed for VF. As such, there is an urgent unmet
need to develop a vaccine that can provide protection from the disease. Evidence suggests an effective vaccine
for VF should be possible. Individuals who recover from VF will generally have lifelong immunity against re-
exposure. Furthermore, early studies employing live attenuated vaccine strategies have demonstrated significant
protection in mouse and nonhuman primate models of infection although due to the risk of severe reactogenicity
and genetic reversion, a live attenuated vaccine for human use is not considered a viable approach. Nucleic acid
vaccines, including both DNA and RNA vaccines, result in the intracellular expression of antigens, mimicking a
live infection including induction of robust antibody and T cell responses, but without the risks associated with a
live infection. Recent advances with both DNA and mRNA vaccine technologies have moved them to the forefront
as one of the most effective vaccines strategies to induce protective immunity in humans, as evident by the
current, highly efficacious licensed COVID-19 mRNA vaccines. In addition, DNA and RNA vaccines are rapid
and simple, requiring only the genetic sequence of a given antigen to design. The ease and speed in constructing
and producing DNA and RNA vaccines makes them an ideal tool to enable rapid screening of a large number of
potential antigens to identify novel immunogens for a VF vaccine. Here, we propose to leverage advanced DNA
and RNA vaccine delivery technologies developed at the University of Washington to identify novel immunogens
for a VF vaccine and to investigate their immunogenicity and efficacy in animal models. Toward this goal, in
collaboration with Research Projects 1 and 2 and the Animal Core, we propose to identify a lead nucleic acid
vaccine platform for a VF vaccine (Aim 1), employ that technology to investigate candidate virulence factors and
putative T cell epitopes as protective immunogens to design a lead vaccine composition that affords optimum
immunogenicity, safety and efficacy in mice (Aim 2) and nonhuman primates (Aim 3). If successful, these studies
could lead to development of a novel nucleic acid vaccine that can provide protection from Valley Fever.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigen Presentation><Antigens><Area><Attenuated Vaccines><Biotech><Biotechnology><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19><COVID-19 virus><COVID19><COVID19 virus><CV-19><CV19><Cell Mediated Immunology><Cell-Mediated Immunity><Cellular Immunity><Central America><Class I Genes><Clinical><Clinical Research><Clinical Study><Clinical Trials><CoV-2><CoV2><Coccidioides><Coccidioidomycosis><Collaborations><Communicable Diseases><DNA><DNA Vaccines><Deoxyribonucleic Acid><Desert rheumatism><Development><Disease><Disorder><Epidemiologic Research><Epidemiologic Studies><Epidemiological Studies><Epidemiology Research><Exhibits><Genetic><Geography><Goals><Grippe><Health><Human><Humoral Immunities><Immune><Immune response><Immunes><Immunity><Immunologic Stimulation><Immunological Stimulation><Immunological response><Immunostimulation><Incidence><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Influenza Vaccines><Lead><Licensing><Live-attenuated Vaccine><M nemestrina><M. nemestrina><MHC Class I><MHC Class I Genes><Macaca nemestrina><Mexico><Mice><Mice Mammals><Modeling><Modern Man><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><Naked DNA Vaccines><Non-Polyadenylated RNA><Nucleic Acid Vaccines><Nucleic Acids><Pathogenesis><Pathogenicity Factors><Pb element><Pigtail Macaque><Pigtail Monkey><Play><Pneumonia><Pre-Clinical Model><Preclinical Models><Predisposition><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><RNA><RNA Gene Products><RNA vaccine><RNA-based vaccine><Rapid screening><Recombinant DNA Vaccines><Regimen><Research Grants><Research Project Grants><Research Projects><Ribonucleic Acid><Risk><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><San Joaquin Valley fever><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><South America><Speed><Susceptibility><T cell response><T-Cell Epitopes><T-Lymphocyte Epitopes><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Technology><Universities><Vaccination><Vaccine Antigen><Vaccines><Valley Fever><Virulence><Virulence Factors><Washington><Wuhan coronavirus><antibody-based immunity><community acquired pneumonia><community associated pneumonia><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><deliver vaccines><desert fever><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><epidemiologic investigation><epidemiology study><experiment><experimental research><experimental study><experiments><flu vaccine><flu virus vaccine><hCoV19><heavy metal Pb><heavy metal lead><high risk><host response><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><in vivo><influenza virus vaccine><lead candidate><live vaccine><live vaccines><mRNA vaccine><mRNA-based vaccine><model of animal><mouse model><murine model><nCoV2><non-human primate><nonhuman primate><novel><nucleic acid-based vaccine><outcome following vaccination><outcome following vaccine><pathogenicity gene><pig-tailed macaque><pre-clinical><preclinical><protective efficacy><result following vaccination><result following vaccine><social role><success><tool><vaccination outcome><vaccination result><vaccination study><vaccination trial><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine delivery><vaccine development><vaccine outcome><vaccine platform><vaccine result><vaccine strategy><vaccine study><vaccine trial><virulence gene><virulent gene>